Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Tumor Targeting Via EPR: Strategies To Enhance Patient Responses.

Susanne K Golombek, Jan-Niklas May, B. Theek, Lia Appold, N. Drude, F. Kiessling, T. Lammers
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5-10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.
This paper references
10.1016/j.addr.2012.10.002
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
H. Maeda (2013)
10.1093/JNCI/DJK005
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
A. M. Ponce (2007)
10.1016/j.ctrv.2014.12.012
Drug radiotherapy combinations: review of previous failures and reasons for future optimism.
G. Higgins (2015)
10.1631/jzus.B1600303
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
M. Zhao (2017)
10.1038/natrevmats.2017.24
Rethinking cancer nanotheranostics.
H. Chen (2017)
10.1016/0360-3016(95)02137-X
Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: A prospectively controlled randomized study by the radiation therapy oncology group
B. Emami (1993)
10.4155/tde-2017-0118
Nanomedicine: is it lost in translation?
K. Greish (2018)
10.2217/NNM-2016-0233
Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant.
Karin Binnemars-Postma (2016)
10.1016/j.biomaterials.2012.09.064
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy.
M. Talelli (2013)
Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation.
C. Harding (1991)
10.7150/thno.21670
Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines
H. Lee (2018)
10.1038/427695A
Pathology: Cancer cells compress intratumour vessels
T. Padera (2004)
10.1124/MI.7.4.8
Optimizing combination chemotherapy by controlling drug ratios.
L. Mayer (2007)
10.1053/CTRV.2001.0232
Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy.
A. Witkamp (2001)
10.1023/A:1018907715905
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs
A. Gabizon (2004)
10.1073/pnas.1018892108
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
B. Diop-Frimpong (2011)
10.1016/j.jconrel.2011.05.022
APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
Michael Dunne (2011)
10.1038/nature23647
Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors
Elizabeth Stewart (2017)
10.1016/j.cell.2015.03.053
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
M. Wetering (2015)
10.18632/ONCOTARGET.227
A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles
Yuan Qiao (2011)
10.3109/02656739609023525
Simulation studies promote technological development of radiofrequency phased array hyperthermia.
P. Wust (1996)
10.1038/sj.cgt.7701026
Local delivery system of cytotoxic agents to tumors by focused sonoporation
K. Iwanaga (2007)
10.1200/JCO.2012.46.3653
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
R. Jain (2013)
10.1016/0360-3016(94)90154-6
Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients.
R. Valdagni (1994)
10.1016/j.jconrel.2011.12.011
Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model.
Ashish Ranjan (2012)
10.1016/j.addr.2010.03.011
Tumor delivery of macromolecular drugs based on the EPR effect.
V. Torchilin (2011)
10.1016/S0301-5629(99)00048-4
Ultrasound technology for hyperthermia.
C. Diederich (1999)
10.3109/1061186X.2012.723213
Biological rationale for the design of polymeric anti-cancer nanomedicines
Y. Zhou (2013)
10.1158/0008-5472.CAN-12-4561
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
Uma Prabhakar (2013)
10.1074/jbc.270.48.28790
Effect of Ionizing Radiation on AP-1 Binding Activity and Basic Fibroblast Growth Factor Gene Expression in Drug-sensitive Human Breast Carcinoma MCF-7 and Multidrug-resistant MCF-7/ADR Cells *
Y. J. Lee (1995)
10.1200/JCO.2008.26.15_SUPPL.4108
A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC)
G. Batist (2008)
10.1016/j.cell.2011.08.039
Basic and Therapeutic Aspects of Angiogenesis
M. Potente (2011)
10.1016/j.xphs.2017.06.019
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
Az Alddien Natfji (2017)
10.1200/JCO.2010.30.5961
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
E. Feldman (2011)
10.1038/srep27559
Core-shell nanocarriers with high paclitaxel loading for passive and active targeting
Z. Jin (2016)
10.1038/nrc.2017.17
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip J. Gotwals (2017)
10.1093/jjco/hyp074
Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
A. Nagamitsu (2009)
10.1111/j.1349-7006.2011.01954.x
New concept of cytotoxic immunoconjugate therapy targeting cancer‐induced fibrin clots
M. Yasunaga (2011)
10.1016/j.biomaterials.2014.04.060
Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model.
A. Astashkina (2014)
10.1016/j.jvir.2011.10.018
Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
B. Wood (2012)
10.1016/j.jconrel.2010.01.025
To PEGylate or not to PEGylate, that is not the question.
K. Park (2010)
10.1038/s41598-017-09116-1
Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers
Y. Liu (2017)
10.1016/J.NANTOD.2010.05.001
Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy
T. Lammers (2010)
10.1016/S0026-2862(03)00057-8
Solid stress generated by spheroid growth estimated using a linear poroelasticity model.
Tiina Roose (2003)
10.2147/IJWH.S55552
Benefits, risks, and safety of external beam radiation therapy for breast cancer
L. Brown (2015)
10.1021/acsnano.7b07214
New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics.
A. Nel (2017)
Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure.
R. Zlotecki (1993)
10.1186/bcr3621
Trastuzumab emtansine: mechanisms of action and drug resistance
Márk Barok (2014)
10.1016/j.addr.2014.01.008
Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.
Muna Aryal (2014)
10.1021/nn402662d
Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier.
Y. Miura (2013)
10.1016/J.NANTOD.2017.08.001
Thermosensitive nanomedicines could revolutionize thermal therapy in oncology
Michael Dunne (2017)
10.1152/physrev.00038.2010
Normalization of the vasculature for treatment of cancer and other diseases.
S. Goel (2011)
10.1097/00000658-199612000-00011
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
A. Eggermont (1996)
10.1056/NEJM197111182852108
Tumor angiogenesis: therapeutic implications.
J. Folkman (1971)
10.1016/j.jconrel.2014.03.007
Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging.
B. Theek (2014)
10.1038/nm.1971
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging
B. Vakoc (2009)
10.1063/1.1643544
Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agents
Susannah H. Bloch (2004)
10.1038/nm879
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation
E. Brown (2003)
10.1016/j.jconrel.2017.03.006
PBCA‐based polymeric microbubbles for molecular imaging and drug delivery
Patrick Koczera (2017)
10.1021/jacs.6b09538
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.
X. Duan (2016)
10.1016/j.chembiol.2017.06.012
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
F. Weeber (2017)
10.1021/nl404391r
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines.
S. Kunjachan (2014)
10.1007/s00441-008-0675-8
VEGF inhibition: insights from preclinical and clinical studies
Y. Crawford (2008)
10.1126/science.1171362
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
K. Olive (2009)
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.
Y. Boucher (1990)
10.1016/j.jconrel.2016.10.007
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
Georg Dimcevski (2016)
10.1146/annurev-chembioeng-061010-114300
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies.
Vikash P. Chauhan (2011)
10.1021/mp3002733
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
F. Danhier (2012)
10.1002/wnan.1358
Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Samuel S Linton (2016)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1038/nrd.2017.34
Lessons from immuno-oncology: a new era for cancer nanomedicine?
Wen Jiang (2017)
10.1093/jnci/91.24.2081
Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma.
G. Calais (1999)
10.1002/1097-0142(19880801)62:3<467::AID-CNCR2820620304>3.0.CO;2-Y
Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma
S. Noguchi (1988)
Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature.
G. Kong (2001)
10.7150/thno.11304
Erythropoietin Improves the Accumulation and Therapeutic Effects of Carboplatin by Enhancing Tumor Vascularization and Perfusion
D. Doleschel (2015)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
K. Harrington (2001)
10.1056/NEJMoa1304369
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
D. V. Von Hoff (2013)
10.1084/JEM.133.2.275
ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
J. Folkman (1971)
10.1038/nnano.2017.52
A STING-Activating Nanovaccine for Cancer Immunotherapy
Min Luo (2017)
10.1158/1535-7163.MCT-06-0118
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
L. Mayer (2006)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
10.1021/acs.nanolett.7b01171
Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers.
Y. Tsvetkova (2017)
10.1080/028418600430789
High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.
M. Koukourakis (2000)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
10.1016/j.biomaterials.2016.06.032
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
Xiao Zhao (2016)
10.1111/j.1751-1097.1995.tb09150.x
SITES OF PHOTODAMAGE in vivo and in vitro BY A CATIONIC PORPHYRIN
D. Kessel (1995)
10.1158/1535-7163.MCT-15-0764
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
H. Kim (2016)
10.3109/02656736.2014.936049
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
T. Zagar (2014)
10.1021/bc200158j
Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.
M. Yasunaga (2011)
10.1016/S1470-2045(17)30312-1
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
V. Diéras (2017)
10.1111/j.1349-7006.1988.tb01563.x
Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue
Yasuhiro Matsumura (1988)
10.1007/978-1-4419-0131-6_3
Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor
T. Seki (2009)
10.1016/S0002-9440(10)65006-7
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
10.1038/nrc.2016.91
Mouse models in oncoimmunology
L. Zitvogel (2016)
10.1038/NATREVMATS.2016.14
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm (2016)
10.1016/0360-3016(77)90013-X
Hyperthermia and radiation--a selective thermal effect on chronically hypoxic tumor cells in vivo.
W. Dewey (1977)
10.1016/j.cell.2017.01.034
How Much Longer Will We Put Up With $100,000 Cancer Drugs?
P. Workman (2017)
10.1093/JNCI/82.1.4
What is the evidence that tumors are angiogenesis dependent?
J. Folkman (1990)
10.1038/sj.onc.1204258
Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways
J. Park (2001)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1158/1078-0432.CCR-05-0343
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Kimberley M Laginha (2005)
10.1021/nn305011p
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors.
K. Sano (2013)
10.1021/acsnano.6b06245
Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood.
S. MacParland (2017)
10.1126/SCIENCE.1082504
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
M. García-Barros (2003)
10.1038/bjc.1993.179
Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.
C. J. Li (1993)
10.1093/annonc/mdn169
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
C. Grávalos (2008)
10.1016/j.jconrel.2012.05.007
Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles.
S. Fokong (2012)
10.1016/j.ddtec.2016.07.007
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects.
A. Dasgupta (2016)
10.1038/nrc3958
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
H. Barker (2015)
10.1016/j.ddtec.2011.11.010
Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet?
K. Greish (2012)
10.1021/acsnano.5b01288
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
H. Zhou (2015)
10.1186/s40169-018-0185-6
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
H. Maeda (2018)
10.1093/neuonc/nos135
In vivo models of primary brain tumors: pitfalls and perspectives
P. C. Huszthy (2012)
10.1158/2159-8290.CD-14-0001
Patient-derived xenograft models: an emerging platform for translational cancer research.
M. Hidalgo (2014)
10.1016/0277-5379(83)90418-2
On the receiving end--patient perception of the side-effects of cancer chemotherapy.
A. Coates (1983)
10.1073/pnas.1213353109
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
T. Stylianopoulos (2012)
10.1158/1535-7163.MCT-10-0470
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Curtis B. Thompson (2010)
10.2165/00003088-200544080-00003
Clinical Pharmacokinetics of Losartan
D. Sica (2005)
10.1038/ncomms3516
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan (2013)
10.1016/j.jconrel.2016.07.018
Macrophage-based cell therapies: The long and winding road.
S. Lee (2016)
Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft.
C. A. Znati (1996)
10.1038/sj.bjc.6604929
Why are tumour blood vessels abnormal and why is it important to know?
J. Nagy (2009)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.
G. Kong (2000)
10.1016/J.JCONREL.2006.10.032
Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems.
T. Lammers (2007)
10.1016/j.addr.2017.07.007
Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Tarun Ojha (2017)
10.1038/nnano.2012.45
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
Vikash P. Chauhan (2012)
10.1038/S41551-017-0029
Designing nanomedicine for immuno-oncology
W. Jiang (2017)
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
F. Pastorino (2003)
10.1016/j.ccell.2014.10.015
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Ping-Pui Wong (2015)
10.1038/ncomms11838
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Carlos Pérez-Medina (2016)
10.1182/BLOOD.V100.4.1334.H81602001334_1334_1339
Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF.
Josef Friedl (2002)
Transport of molecules in the tumor interstitium: a review.
R. Jain (1987)
10.1053/J.SEMINONCOL.2005.11.011
Renal toxicities of chemotherapy.
M. D. de Jonge (2006)
10.1038/d41586-018-04161-w
Cancer research with a human touch
M. May (2018)
10.1126/scitranslmed.aal0225
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Miles A. Miller (2017)
10.1016/j.gendis.2014.12.002
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Jillian M Cathcart (2015)
10.1111/j.1442-200X.1991.tb01570.x
Angiotensin‐Induced Hypertension Chemotherapy in Children with Advanced Solid Tumors
Y. Fujii (1991)
10.1016/j.smim.2017.09.002
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.
H. Shen (2017)
10.3389/fchem.2014.00105
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
João Conniot (2014)
10.1111/J.1349-7006.1991.TB01797.X
Fluctuations in Tumor Blood Flow under Normotension and the Effect of Angiotensin II‐induced Hypertension
K. Hori (1991)
10.1111/j.1349-7006.2000.tb00940.x
Tumor‐selective Blood Flow Decrease Induced by an Angiotensin Converting Enzyme Inhibitor, Temocapril Hydrochloride
K. Hori (2000)
10.1038/ncomms12499
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
Chunbai He (2016)
10.2147/IJN.S68882
Quantification of transient increase of the blood–brain barrier permeability to macromolecules by optimized focused ultrasound combined with microbubbles
Lingyan Shi (2014)
10.1158/0008-5472.CAN-03-0576
Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts
C. Davies (2004)
10.1038/sj.bjc.6604561
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
T. Lammers (2008)
10.1016/j.addr.2011.12.010
Cancer stromal targeting (CAST) therapy.
Y. Matsumura (2012)
10.1158/1078-0432.CCR-16-1990
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
R. Ramanathan (2017)
10.1634/THEONCOLOGIST.11-4-397
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.
R. van Horssen (2006)
10.1016/S1470-2045(17)30457-6
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
H. Wasan (2017)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1038/NATREVMATS.2016.69
Cancer nanomedicine: Is targeting our target?
T. Lammers (2016)
10.1038/NATREVMATS.2016.76
Erratum: Cancer nanomedicine: is targeting our target?
T. Lammers (2016)
10.1016/j.jconrel.2014.03.041
Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses.
S. Keller (2014)
10.1016/j.jconrel.2010.09.004
New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization.
S. Tinkov (2010)
10.1038/d41586-018-03841-x
Organoids reveal cancer dynamics
C. Kuo (2018)
10.3816/CBC.2000.S.015
The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors
H. M. Verheul (2000)
10.1038/nrc.2017.93
Transport of drugs from blood vessels to tumour tissue
M. Dewhirst (2017)
10.1016/J.YEXCR.2005.11.026
Discovery of vascular permeability factor (VPF).
H. Dvorak (2006)
10.14670/HH-14.461
Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia.
P. Peschke (1999)
10.1016/j.ajpath.2013.10.014
Micro-CT imaging of tumor angiogenesis: quantitative measures describing micromorphology and vascularization.
J. Ehling (2014)
10.1158/0008-5472.CAN-13-3494
Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment.
K. Yokoi (2014)
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
G. Griffon-Etienne (1999)
10.1021/ACSAMI.6B10175
Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy.
Yanna Cui (2016)
10.1093/annonc/mds172
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
C. Verschraegen (2012)
10.1158/0008-5472.CAN-09-1947
Drug combination studies and their synergy quantification using the Chou-Talalay method.
T. Chou (2010)
10.7863/jum.2010.29.1.61
Antitumor Effect of Docetaxel‐Loaded Lipid Microbubbles Combined With Ultrasound‐Targeted Microbubble Activation on VX2 Rabbit Liver Tumors
Juan Kang (2010)
10.4155/tde-2017-0071
Integration of nano drug-delivery system with cancer immunotherapy.
T. Nakamura (2017)
10.1016/j.leukres.2008.06.028
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
P. Tardi (2009)
10.1158/1078-0432.CCR-16-3193
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
H. Lee (2017)
10.2217/hep-2016-0005
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
R. Lencioni (2016)
10.1016/j.jconrel.2016.11.015
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
F. Danhier (2016)
10.1158/1535-7163.MCT-13-0633
The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy
K. Sano (2013)
10.2174/187152010794728639
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
C. Mas-Moruno (2010)
10.1371/journal.pone.0047453
Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model
Astrid Gasselhuber (2012)
10.1158/1078-0432.CCR-05-1673
Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications
B. Chen (2006)
10.1158/0008-5472.CAN-06-2117
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
F. Pastorino (2006)
10.1097/00000421-199104000-00008
Randomized Phase III Study Comparing Irradiation and Hyperthermia with Irradiation Alone in Superficial Measurable Tumors: Final Report by the Radiation Therapy Oncology Group
C. Perez (1991)
10.1101/cshperspect.a006536
Tumor endothelial cells.
A. Dudley (2012)
10.1016/j.jconrel.2012.04.038
Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.
H. Maeda (2012)
10.1007/s00401-014-1272-4
Human pontine glioma cells can induce murine tumors
V. Caretti (2014)
10.1002/adfm.201401199
Theranostic USPIO-Loaded Microbubbles for Mediating and Monitoring Blood-Brain Barrier Permeation.
T. Lammers (2015)
10.1002/(SICI)1097-4652(199810)177:1<137::AID-JCP15>3.0.CO;2-A
Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever‐like) whole body hyperthermia
R. Burd (1998)
10.1016/j.biomaterials.2018.03.036
Engineering nanoparticle strategies for effective cancer immunotherapy.
H. Yoon (2018)
10.3389/fonc.2015.00224
Targeting ECM Disrupts Cancer Progression
F. A. Venning (2015)
10.1200/JCO.2016.34.15_SUPPL.7000
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
J. Lancet (2016)
10.1016/S1011-1344(97)00127-9
Mitochondrial photodamage and PDT-induced apoptosis.
D. Kessel (1998)
10.1126/scitranslmed.aac6522
Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle
Miles A. Miller (2015)
10.1016/j.jconrel.2018.04.026
Multi‐modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models
Einar Sulheim (2018)
10.1038/s41551-017-0139-0
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
N. Tanaka (2017)
10.1016/j.addr.2008.03.005
Microbubbles in ultrasound-triggered drug and gene delivery.
S. Hernot (2008)
10.1016/j.ultrasmedbio.2012.04.015
Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma.
Lisa Treat (2012)
10.3390/ijms18030600
The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma
D. Kudo (2017)
10.1021/mp800030k
Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model
Lilian E van Vlerken (2008)
10.1562/0031-8655(2000)072<0533:SRTPT>2.0.CO;2
Scavenger-Receptor Targeted Photodynamic Therapy¶
M. Hamblin (2000)
10.3322/caac.20114
Photodynamic therapy of cancer: An update
P. Agostinis (2011)
10.1038/nature18300
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
L. Kranz (2016)
10.1200/JCO.2015.33.3_SUPPL.366
Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience.
K. Krishna (2015)
10.1109/22.539932
Temperature control and thermal dosimetry by microwave radiometry in hyperthermia
L. Dubois (1996)
10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Y. Bang (2010)
10.1200/JCO.2007.14.8841
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
M. Machtay (2008)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1158/0008-5472.CAN-04-0074
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
R. Tong (2004)
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
M. Cuello (2001)
10.1001/jamaoncol.2017.4941
Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma.
M. Dewhirst (2018)
10.1158/0008-5472.CAN-12-1683
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.
A. Manzoor (2012)
10.1038/s41586-018-0024-3
Intra-tumour diversification in colorectal cancer at the single-cell level
Sophie F. Roerink (2018)
10.1016/j.jconrel.2016.02.021
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR.
B. Theek (2016)
10.1186/s12645-016-0024-7
Application of nanotechnology to cancer radiotherapy
Yu Mi (2016)
10.1016/j.ymeth.2017.05.018
Recent advances in ultrasound-based diagnosis and therapy with micro- and nanometer-sized formulations.
N. Güvener (2017)
10.1158/0008-5472.CAN-11-2464
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
A. G. Sorensen (2012)
10.1007/978-1-4614-7876-8_8
Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots
S. Taurin (2013)
10.1038/srep21417
An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors
A. Karageorgis (2016)
10.1038/ncomms9692
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
Miles A. Miller (2015)
10.1073/pnas.0914140107
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
C. Choi (2009)
10.1016/j.addr.2016.04.025
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
J. I. Hare (2017)
10.1111/j.1751-1097.1991.tb03669.x
THE PHOTODEGRADATION OF PORPHYRINS IN CELLS CAN BE USED TO ESTIMATE THE LIFETIME OF SINGLET OXYGEN
J. Moan (1991)
10.1093/OXFORDJOURNALS.ANNONC.A059322
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies.
D. Berger (1995)
10.1200/JCO.1998.16.9.2906
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a
H. S. Koops (1998)
10.1016/j.nano.2016.09.015
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models.
A. T. Lucas (2017)



This paper is referenced by
10.1016/j.cej.2020.126443
Solvent mixing generating air bubbles as a template for polydopamine nanobowl fabrication: Underlying mechanism, nanomotor assembly and application in cancer treatment
Qichen Zhan (2021)
10.1016/j.radonc.2020.06.041
Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials.
Moataz Reda (2020)
10.3390/bioengineering7030111
Biomimetic Nanocarriers for Cancer Target Therapy
Clara Guido (2020)
10.1186/s12951-019-0534-7
18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts
Yanshu Wang (2019)
10.1016/j.canlet.2019.01.002
Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation.
Jingyan Tian (2019)
10.7150/thno.37543
EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles
G. Bort (2020)
10.3390/ijms21176029
Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment
Anne-Kathrin Noack (2020)
10.7150/thno.43402
Multifunctional PVCL nanogels with redox-responsiveness enable enhanced MR imaging and ultrasound-promoted tumor chemotherapy
Fang Xu (2020)
10.2147/IJN.S184912
Characterization, optimization, and in vitro evaluation of Technetium-99m-labeled niosomes
Leanne De Silva (2019)
10.2217/nnm-2018-0479
A cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment.
X. Jin (2020)
10.1016/bs.enz.2018.08.002
Organosilica Nanoparticles and Medical Imaging.
M. Nakamura (2018)
10.1039/d0bm00558d
The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives.
R. Foulkes (2020)
10.1016/j.jconrel.2020.11.063
Manipulating dynamic tumor vessel permeability to enhance polymeric micelle accumulation.
Y. Inoue (2020)
Manuscript for “The EPR effect and beyond: Strategies to improve tumor targeting and nanomedicine efficacy” Special Issue. Manuscript submission number 37543w2 Title EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles Authors
Guillaume Bort (2019)
Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy
Rao (2020)
10.1016/j.ajps.2019.10.001
The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy
Xiaoli Zhang (2020)
10.1016/j.jconrel.2020.01.008
Ferroptosis-driven nanotherapeutics for cancer treatment.
Xinzhu Shan (2020)
10.1016/j.xphs.2020.10.019
Vegetable Oil-basedHybrid Submicron Particles Loaded with JMV5038: A Promising Formulation against Melanoma.
Koceïla Doufène (2020)
10.3390/cancers12020295
Riboflavin-Targeted Drug Delivery
Milita Darguzyte (2020)
10.3390/ijms21165832
Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix
A. Kowalczyk (2020)
10.1002/wnan.1588
Critical considerations for targeting colorectal liver metastases with nanotechnology
Usman Arshad (2019)
10.1186/s12951-020-00654-x
Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells
Yazan Haddad (2020)
10.1002/wnan.1689
The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules.
Antonella Grigoletto (2020)
10.1016/j.jconrel.2020.05.014
Tumor-responsive dynamic nanoassemblies for targeted imaging, therapy and microenvironment manipulation.
L. Low (2020)
10.1016/j.eurpolymj.2020.109481
Reactive-ester derived polymer nanogels for cancer immunotherapy
Judith Stickdorn (2020)
10.1007/s11706-020-0526-4
Hollow mesoporous silica nanoparticles as nanocarriers employed in cancer therapy: A review
Yimin Zhou (2020)
10.1002/adtp.202000136
Nanomedicine for the Treatment of Advanced Prostate Cancer
Sonia Vicente-Ruiz (2020)
10.3390/nano10050834
Fe/Mg-Modified Carbonate Apatite with Uniform Particle Size and Unique Transport Protein-Related Protein Corona Efficiently Delivers Doxorubicin into Breast Cancer Cells
Sheikh Tanzina Haque (2020)
10.1016/j.ejmech.2019.01.007
Composition design and medical application of liposomes.
Mingyuan Li (2019)
10.1016/j.ejpb.2020.06.004
A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release.
Shakti Nagpal (2020)
10.1007/s13346-020-00722-7
In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
Inés Luis de Redín (2020)
10.1039/d0nr01547d
A HMCuS@MnO2 nanocomplex responsive to multiple tumor environmental clues for photoacoustic/fluorescence/magnetic resonance trimodal imaging-guided and enhanced photothermal/photodynamic therapy.
Q. Li (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar